ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C7H4ClNO2
CAS番号:
分子量:
169.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
202-403-9
MDL number:
InChI key
TZFWDZFKRBELIQ-UHFFFAOYSA-N
InChI
1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
SMILES string
Clc1ccc2OC(=O)Nc2c1
assay
≥98% (TLC)
form
powder
color
white to off-white
mp
191-192 °C (lit.)
solubility
DMSO: 50 mg/mL, clear
originator
Johnson & Johnson
storage temp.
room temp
Quality Level
Gene Information
human ... KCNN4(3783)
類似した製品をお探しですか? 訪問 製品比較ガイド
関連するカテゴリー
Application
Chlorzoxazone may be used:
- as a calcium-activated potassium (KCa) channel activator in patch-clamp electrophysiology to test its effect on dendritic hyperexcitability
- as a substrate for cytochrome P450 2E1 (CYP2E1) enzyme in cultured human hepatocytes
- as a benzimidazolone compound to test its effect on epithelial sodium (Na+) transport
Biochem/physiol Actions
Chlorzoxazone inhibits the multisynaptic reflex arcs primarily in the spinal cord and brain subcortical areas. It is an activator of calcium activated potassium channels and may contribute to the aortic artery relaxation in mice. Chlorzoxazone also activates the calcium-activated potassium (KCa) channel and small conductance calcium-activated potassium channels (SK). It is metabolized by cytochrome P450 2E1 (CYP2E1) and serves as a probe for monitoring this enzyme function.
Chlorzoxazone is a skeletal muscle relaxant.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
C4397-VAR: + C4397-BULK: + C4397-25G: + C4397-100G:
jan
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7258-7268 (2010-05-28)
Episodic ataxia type 2 (EA2) is a hereditary cerebellar ataxia associated with mutations in the P/Q-type voltage-gated calcium (Ca(2+)) channels. Therapeutic approaches for treatment of EA2 are very limited. Presently, the potassium (K(+)) channel blocker 4-aminopyridine (4-AP) constitutes the most
B J Powers et al.
Archives of internal medicine, 146(6), 1183-1186 (1986-06-01)
A drug rechallenge proved chlorzoxazone to be hepatotoxic in a patient who had been treated with a combination of it and acetaminophen (Parafon Forte) for several months. Failure to demonstrate a toxic response to acetaminophen coupled with a dramatic response
Sanjeev Kumar et al.
International journal of applied & basic medical research, 4(2), 101-105 (2014-08-22)
The fixed dose combinations (FDCs) of muscle relaxants, non-steroidal anti-inflammatory drugs and paracetamol are commonly prescribed in the treatment of acute lower backache. The present study was undertaken with the aim of comparing the efficacy and safety of FDCs of
C A Syme et al.
American journal of physiology. Cell physiology, 278(3), C570-C581 (2000-03-11)
We previously characterized 1-ethyl-2-benzimidazolinone (1-EBIO), as well as the clinically useful benzoxazoles, chlorzoxazone (CZ), and zoxazolamine (ZOX), as pharmacological activators of the intermediate-conductance Ca(2+)-activated K(+) channel, hIK1. The mechanism of activation of hIK1, as well as the highly homologous small-conductance
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7249-7257 (2010-05-28)
Episodic ataxia type-2 (EA2) is an inherited movement disorder caused by mutations in the gene encoding the Ca(v)2.1alpha1 subunit of the P/Q-type voltage-gated calcium channel that result in an overall reduction in the P/Q-type calcium current. A consequence of these
資料
Discover Bioactive Small Molecules for ADME/Tox
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)